A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL.
Blood. 2022 Oct 20;140(16):1790-1802. doi: 10.1182/blood.2022016243.
Blood. 2022.
PMID: 35981465